Bicycle Therapeutics
Generated by Meeveem AI
"Developing precision-guided bicyclic peptide therapeutics to penetrate deep into solid tumours"
Cambridge
•51 - 250 Employees
•Clinical Systems
About Bicycle Therapeutics
Bicycle Therapeutics pioneers bicyclic peptides, or Bicycles, a novel class of chemically synthesised molecules combining biologics' precision with small molecule advantages. Designed to penetrate solid tumours, these constrained therapeutics target cancers resistant to conventional treatments. Founded in 2009 on Nobel Prize-winning research by Sir Greg Winter, Bicycle advances clinical trials in oncology and beyond. Operating from Cambridge, UK and Lexington, Massachusetts, the company develops therapeutics with rapid tissue penetration and tuneable pharmacokinetics that minimise toxicities. Bicycle molecules engage intractable protein targets, addressing unmet medical needs through pharmaceutical partnerships and academic collaborations.
Illustrative visual - may not reflect the actual offering.
Illustrative visual - may not reflect the actual offering.
200
Team Members
2009
Founded
Public
Funding
On-Site
Work Environment
Our Vision
A world where precision-guided therapeutics transform outcomes for patients with solid tumours and diseases once considered intractable to conventional medicine.
Our Mission
At Bicycle, our mission is to create unique, impactful medicines that transform the lives of the largest possible number of patients.